Pfizer leads $123M financing round for precision medicine company

Pfizer Ventures co-led a $123 million series B financing round for Flare Therapeutics, a biotech company working to discover precision medicines for cancer and other diseases.

The company will use the proceeds from the financing to support clinical trials for FX-909, a small molecule inhibitor targeting the peroxisome proliferator-activated receptor gamma (PPARG). 

Additionally, the company will look to nominate at least one other development candidate from the company's research pipeline in 2024, according to a March 22 Flare news release.

GordonMD Global Investments co-led the round with Pfizer.

"Transcription factors have long been viewed as prime therapeutic targets playing a key role in a broad range of diseases, particularly cancers, where they represent one-third of all oncogenes. While targeting transcription factors has the potential for incredible impact, their complex structure makes them notoriously difficult to drug, requiring a new approach and new thinking," Flare Chief Scientific Officer and co-founder Rob Sims, PhD, said in the release.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like

 

Featured Whitepapers

Featured Webinars